SCHEMBL7608249

SCHEMBL7608249

CCN(CC)c1ccc(/C=C(\C)C(=O)c2ccc(OC)c(OC)c2OC)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 7/20 0.52
▸ FGFR1 P11362 2/20 0.44
▸ TUBB4A P04350 2/20 0.44
▸ TUBB P07437 2/20 0.44
▸ TUBA3C P0DPH7 2/20 0.44
▸ TUBA1B P68363 2/20 0.44
▸ TUBA4A P68366 2/20 0.44
▸ TUBB4B P68371 2/20 0.44
▸ TUBB3 Q13509 2/20 0.44
▸ TUBB2A Q13885 2/20 0.44
▸ TUBB8 Q3ZCM7 2/20 0.44
▸ TUBA3E Q6PEY2 2/20 0.44
▸ TUBA1A Q71U36 2/20 0.44
▸ TUBA1C Q9BQE3 2/20 0.44
▸ TUBB6 Q9BUF5 2/20 0.44
▸ TUBB2B Q9BVA1 2/20 0.44
▸ ALDH1A1 P00352 7/20 0.42
▸ GAA P10253 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7608252 1.00 TUBB1 (0.52) TUBB1FGFR1TUBB4ATUBBTUBA3C
SCHEMBL7614519 0.87 FGFR1 (0.43) TUBB1FGFR1ALDH1A1GAAKDM4E
SCHEMBL7614524 0.87 FGFR1 (0.43) TUBB1FGFR1ALDH1A1GAAKDM4E
SCHEMBL7613324 0.86 TUBB1 (0.68) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL7613323 0.86 TUBB1 (0.68) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL7552059 0.82 TUBB1 (0.77) TUBB1FGFR1ALDH1A1GAAKDM4E
SCHEMBL7552056 0.82 TUBB1 (0.77) TUBB1FGFR1ALDH1A1GAAKDM4E
SCHEMBL7611033 0.82 TUBB1 (0.62) TUBB1FGFR1TUBB4ATUBBTUBA3C
SCHEMBL7611037 0.82 TUBB1 (0.62) TUBB1FGFR1TUBB4ATUBBTUBA3C
SCHEMBL7587229 0.80 TUBB1 (0.62) TUBB1FGFR1ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020143064-A1 Novel use of compounds of the chalcones class AVENTIS PHARMA S.A. (FR) 2002-10-03 — — US claimed
US-20020143064-A1 Novel use of compounds of the chalcones class AVENTIS PHARMA S.A. (FR) 2002-10-03 — — US disclosed
EP-0288794-B1 Controlling the growth of tumor tissue with chalcone derivatives MERRELL DOW PHARMA (US) 1994-06-08 — — EP disclosed
EP-0286083-B1 METHOD OF TREATING MULTIPLE SCLEROSIS WITH CHALCONE DERIVATIVES MERRELL DOW PHARMACEUTICALS INC. (US) 1993-08-04 — — EP disclosed
EP-0287901-B1 METHODS FOR TREATING GOUT WITH CHALCONE DERIVATIVES MERRELL DOW PHARMACEUTICALS INC. (US) 1990-08-01 — — EP disclosed
US-4904697-A Controlling the growth of certain tumor tissue with chalcone derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1990-02-27 — — US disclosed
US-4863968-A Methods of treating gout with chalcone derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-09-05 — — US disclosed
US-4753965-A INHIBITING DESTRUCTION OF MYELIN SHEATH; ANTIMITOTIC MERRELL DOW PHARMACEUTICALS, INC. (US) 1988-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143064-A1 Novel use of compounds of the chalcones class NR2E1, FLT1, KDR TUBB1 304/4885FGFR1 252/4885TUBB4A 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback